Accelerate Diagnostics Inc. (AXDX) Overvalued by -9.54%

Publicly-traded company Accelerate Diagnostics Inc. (NASDAQ:AXDX) had a closing price of $16.07 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $14.67, this means that the stock is overpriced by -9.54%. In the past 52 weeks the company’s stock price has moved within the range of $10.23 to $24.00.

This particular stock’s 5-day moving average is 15.62, its 20-day moving average is 16.21 and its 100-day moving average is 18.53. Accelerate Diagnostics Inc. (AXDX) currently has 53.52M shares outstanding, which means that its market capitalization is $860.07M.

The Details: Accelerate Diagnostics Inc. (AXDX) Financial Health

We can also see what the current Return on Assets is for the company, which is a percentage that lets us know how well it is utilizing its net assets to turn a profit. The lower the percentage, the worse the company is making use of its assets. At the moment, Accelerate Diagnostics Inc. Return on Assets is -51.40%.

What Does Wall Street Say about Company?

When investors are considering buying a new stock, they often want to know the general Wall Street consensus on the company – by checking out the average analyst rating, for instance. At the moment, the average analyst rating for AXDX is Hold. Out of 5 total analysts who were surveyed, 1 rated it a sell, 0 rated it a underweight, 0 rated it an overweight, 2 rated it hold, and 2 rated it a Buy.

Understanding Profitability at Accelerate Diagnostics Inc. (AXDX)

Checking out a public company’s Earnings per Share (EPS) is a smart way of assessing its profitability. In the most recent financial results released by Accelerate Diagnostics Inc., for the quarter ending on 12/2019, the company posted EPS of -0.42. The average estimate of Wall Street analysts had projected -0.37.

Wall Street analysts, on average, are forecasting the company’s EPS to be -0.40, compared to -0.41 reported in the same quarter last year. When it comes to net revenue, the average estimate from a total of 5 analysts is 4.66M – compared to 1.82M posted in the year-ago period.